摘要
目的探讨不可逆电穿孔(IRE)联合同种异体NK细胞免疫治疗原发性肝癌的安全性和近期疗效。方法选取2017年1月至2019年8月于本医院诊治的原发性肝癌患者80例为研究对象,80名患者分为IRE组(n=40)和IRENK组(n=40)。记录患者所经历的所有不良事件;评估肿瘤生物标记物(AFP),循环肿瘤细胞(CTCs)、淋巴细胞数量和功能、生活质量、临床反应、无进展生存率(PFS)和总生存率(OS)的变化。结果联合治疗组PFS和OS的均值明显大于单纯IRE组(P<0.05)。IRE联合NK细胞免疫治疗可显著降低CTCs,提高免疫功能和Karnofsky功能状态。结论本研究提示了一种新的、有前途的联合治疗方法,即IRE和异体NK细胞免疫疗法。需要更大规模的临床试验来证实这些结论。
Objective To investigate the safety and short-term efficacy of irreversible electroporation(IRE)combined with allogenic natural killer(NK)cell immunotherapy in the treatment of patients with unresectable primary liver cancer.Methods Between January 2017 and August 2019,80 patients were enrolled and randomly allocated to either the IRE group(n=40)or the IRE-NK group(n=40).All adverse events experienced by the patients were recorded;the changes in tumor biomarkers[AFP,circulating tumor cells(CTCs)],lymphocyte number and function,quality of life,clinical response,progression-free survival(PFS)and overall survival(OS)were assessed.Results Patients who received combination therapy exhibited significantly longer median PFS and OS than who just received IRE(P<0.05).The combination therapy of IRE and NK cell immunotherapy significantly reduced CTCs and increased immune function and Karnofsky performance status.Conclusion Our data suggest a novel,promising combination therapy using IRE and allogenic NK cell immunotherapy.Larger clinical trials are required to con?rm these conclusions.
作者
张伟华
秦艳青
沈金杰
ZHANG Wei-hua;QIN Yan-qing;SHEN Jin-jie(Department of Oncology,Suzhou Integrated Hospital of Traditional Chinese and Western Medicine,Jiangsu215101,China)
出处
《肝脏》
2020年第12期1272-1274,共3页
Chinese Hepatology
基金
江苏省自然科学基金资助项目(BK20181174)
关键词
IRE
NK细胞
原发性肝癌
临床疗效
Irreversible electroporation
Natural killer cells
Primary liver cancer
Clinical trial
作者简介
通信作者:张伟华,Email:xiatiant21@163.com
